Blastic Plasmacytoid Dendritic Cell Neoplasia: A Rare Case Report

Year 2021, , 71 - 72, 07.03.2021

Neslihan Hazel Saydam , İbrahim Ethem Pınar , Tuba Ersal Cumali Yalçın Bedrettin Orhan Ömer Candar , Vildan Ozkocaman , Fahir Özkalemkaş

https://doi.org/10.46310/tjim.876554

Abstract

Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDCN) is a rare hematological malignancy whose pathogenesis has not yet been elucidated. Skin, bone marrow, and lymph node involvement can be observed, and it is generally seen in men and old adults. Immunohistochemistry (IHC) features of skin and bone marrow biopsy are essential for diagnosis. There are no standardized treatment options for this malignancy, and the prognosis is particularly poor. Although there are no standardized treatment options for this malignancy, multiple agent chemotherapies such as Hyper-CVAD and CHOP can be used. Bone marrow transplantation may be an option for patients with life expectancy. More case reports are required to understand and manage this extremely rare malignancy. We report the case we encountered in our clinic and selected CVP as the treatment approach.

Keywords

Blastic plasmacytoid dendritic cell neoplasia, cutaneous lymphoma, NK-cell lymphoma

References

• 1. Zhang YW, Zhong JH, Chen XL, Xiao F, Chen FY. Blastic plasmacytoid dendritic cell neoplasm: A case report and literature review. Exp Ther Med. 2016 Jul;12(1):319-322. doi: 10.3892/etm.2016.3259.
• 2. Shi Y, Wang E. Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review. Arch Pathol Lab Med. 2014 Apr;138(4):564-9. doi: 10.5858/arpa.2013-0101-RS.
• 3. Laribi K, Denizon N, Besançon A, Farhi J, Lemaire P, Sandrini J, Truong C, Ghnaya H, Baugier de Materre A. Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies. Biol Blood Marrow Transplant. 2016 Aug;22(8):1357-1367. doi: 10.1016/j.bbmt.2016.03.022.